United States Molecular Diagnostics Market to Reach $14.01 Billion by 2032

According to recent analysis, the United States Molecular Diagnostics Market was valued at USD 7.98 billion in 2023 and is projected to grow at a CAGR of 6.45%, reaching USD 14.01 billion by 2032. This growth is driven by advancements in genomic and proteomic diagnostics for diseases like cancer, infectious diseases, and genetic disorders.

Market Overview and Key Drivers

Molecular diagnostics has emerged as a crucial tool for identifying genomic variants, enabling early detection, accurate diagnosis, and effective monitoring of diseases. The technology includes PCR, sequencing, and other genetic testing methods that detect specific markers in the genome and proteome. Techniques such as enzyme-linked immunosorbent assay (ELISA) and proteomics have significantly enhanced the diagnostic precision for bacterial, viral, and chronic diseases.

The rising prevalence of chronic diseases such as cancer, genetic disorders, and sexually transmitted infections (STIs) in the United States is a key factor driving market expansion. The American Cancer Society and Centers for Disease Control and Prevention (CDC) report a high number of new cancer cases and genetic diseases, highlighting the increasing adoption of molecular diagnostics for oncology and infectious disease testing.

Technological Advancements: Driving Growth in Diagnostics

Molecular diagnostics are widely used across point-of-care facilities like clinics, retail pharmacies, and physician offices, offering patient-centric solutions. As technological advancements continue to revolutionize the sector, market players are introducing novel testing products that are faster and more efficient. For instance, Huwel Lifesciences developed a portable RT-PCR instrument in February 2023, capable of testing various viral infections in under 30 minutes. Such innovations are helping the market meet growing diagnostic demands.

Moreover, increased government funding for the development of novel test kits is boosting growth. In 2023, companies like Accelerate Diagnostics, Inc. and Redbud Medicine received millions in federal funding to improve molecular diagnostics capabilities. As healthcare-associated infections (HAIs) continue to rise, new initiatives aim to reduce hospital-acquired infections, with programs like the Hospital-Acquired Condition (HAC) Reduction Program by CMS incentivizing hospitals to prioritize infection control.

Market Segmentation

The U.S. molecular diagnostics market is segmented based on technology, applications, products, and end users:

Technology:

• Chips and Microarrays
• In Situ Hybridization
• Sequencing
• Mass Spectrometry (MS)
• PCR
• Other Technologies

Application:

• Pharmacogenomics
• Infectious Disease
• Genetic Disease Screening
• Oncology
• Blood Screening
• Microbiology
• Human Leukocyte Antigen Typing

Products:

• Instruments
• Reagents
• Other Products

End Users:

• Hospitals
• Laboratories
• Other End Users

Leading Companies in the U.S. Molecular Diagnostics Market

The market features strong competition among key players like F Hoffmann-la Roche Ltd, Illumina Ltd, Hologic Corporation, Agilent Technologies Inc., Qiagen NV, Myriad Genetics, Abbott Laboratories, and Danaher Corporation. These companies have focused on product innovation and strategic partnerships to drive their market presence.

Recent Developments:

• QIAGENreceived S. FDA approval for its Therascreen PDGFRA RGQ PCR kit to aid in diagnosing gastrointestinal stromal tumors (GIST) in August 2023.
• BD and CerTest Biotecdeveloped Monkeypox Virus Real-Time PCR Reagents, receiving FDA EUA approval in January 2023.
• Lucira Healthlaunched the first at-home COVID-19 and flu test in March 2023, receiving the first Emergency Use Authorization (EUA) from the FDA for home testing of these viruses.

Future Outlook

The growing demand for early disease detection and the need for personalized healthcare are expected to drive further innovations and expansion in the U.S. molecular diagnostics market. Enhanced POC testing products, rapid diagnostics, and increasing government support will continue to shape the industry's landscape through 2032.

4o

You said:

About Renub Research

Renub Research is a Market Research and Information Analysis company with over 15 years of experience in research, survey, and consulting. We empower companies to make informed business decisions regarding strategy, organization, operations, technology, and mergers & acquisitions. With more than 9,000 syndicated reports and over 750 custom research projects, we supply data to leading organizations such as EMIS, Bloomberg, and Thomson Reuters.

Media Contact

• Company Name: Renub Research
• Contact Person: Rajat Gupta, Marketing Manager
• Phone: +1-478-202-3244 | +91-120-421-9822 (IND)
• Address: 225 Kristie Ln, Roswell, GA 30076
• Email: info@renub.com
• LinkedIn: Renub Research LinkedIn
• Website: renub.com